Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial

BACKGROUND: Serum infliximab trough levels correlate with efficacy; dose escalation is often beneficial in patients with Crohn's disease who stop responding to infliximab treatment. OBJECTIVE: To carry out a post hoc analysis of A Crohn's Disease Clinical Trial Evaluating Infliximab in a N...

Descripción completa

Detalles Bibliográficos
Autores principales: Cornillie, Freddy, Hanauer, Stephen B, Diamond, Robert H, Wang, Jianping, Tang, Kezhen L, Xu, Zhenhua, Rutgeerts, Paul, Vermeire, Séverine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2014
Materias:
Inflammatory Bowel Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4215276/
https://www.ncbi.nlm.nih.gov/pubmed/24474383
http://dx.doi.org/10.1136/gutjnl-2012-304094

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4215276/
https://www.ncbi.nlm.nih.gov/pubmed/24474383
http://dx.doi.org/10.1136/gutjnl-2012-304094

Ejemplares similares